MedPath

UTC Therapeutics Inc

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

2 Phases

Phase 1:1
Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (50.0%)
Phase 1
1 (50.0%)

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

Not Applicable
Recruiting
Conditions
HER2-positive Advanced Malignant Solid Tumors
Interventions
Biological: Anti-HER2 CAR-T cells
First Posted Date
2024-10-26
Last Posted Date
2025-04-16
Lead Sponsor
UTC Therapeutics Inc.
Target Recruit Count
30
Registration Number
NCT06658951
Locations
🇨🇳

The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China

Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

Phase 1
Recruiting
Conditions
Malignant Mesothelioma
Ovary Cancer
Breast Cancer Female
Bile Duct Cancer
Pancreatic Cancer
Colorectal Cancer
Rectal Cancer
First Posted Date
2024-02-13
Last Posted Date
2024-07-24
Lead Sponsor
UTC Therapeutics Inc.
Target Recruit Count
24
Registration Number
NCT06256055
Locations
🇨🇳

Peking University Cancer Hospital & Institute, Beijing, China

News

No news found
© Copyright 2025. All Rights Reserved by MedPath